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ABSTRACT 
 
The interleukin (IL)-13 pathway and its associated transcription factor, signal transducer and activator of 
transcription 6 (STAT6), have been clearly implicated in the pathogenesis of bronchial asthma. We have 
developed a system to effectively screen the STAT6 gene for targeting with small interfering (si) RNA 
molecules. By incorporating an in silico and in vitro screening system we were able to identify fourteen 
siRNA molecules suitable for pre-clinical drug development. Furthermore, we were able to demonstrate that 
modification of certain siRNAs, designed to improve in vivo longevity, was possible without significant loss 
of target knockdown efficacy and that the siRNA produced by our selection process did not induce 
demonstrable interferon responses. These data suggest that several STAT6-targeting siRNA suitable for pre-
clinical development are available for potential use in the treatment of asthma.  
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INTRODUCTION 
 
The recently identified roles of the interleukin (IL)-13 
pathway (Huang et al, 1995; Wills-Karp et al, 1998; Zhu et 
al, 1999; Wills-Karp, 2001; Brightling et al, 2003), the 
Signal Transducer and Activator of Transcription 6 
(STAT6) (Akimoto et al, 1998; Yang et al, 2001; 
Kuperman et al, 2002) protein and epithelial cells (Holgate 
2007; Kato and Schleimer 2007) in the pathogenesis of 
bronchial asthma,  have highlighted this system as a 
potential therapeutic target for asthma (Izuhara et al, 1999; 
Schaefer et al, 2001; Izuhara et al, 2006). While the 
current therapeutic approaches rely on the use of steroid-
based therapies (Adams et al, 2007 Adams et al, 2008a; 
Adams et al, 2008b), our more targeted approach is to 
ablate the inflammatory responses caused by local 
expression of T helper type 2 (Th2) cytokines, which have 
been demonstrated to be associated with the allergic 
asthma phenotype (Larche et al 2003).  In particular, IL-13 
and its associated pathway have been shown to be a key 
component of the asthmatic response, which includes 
eosinophilic infiltration, mucus hyper-secretion, sub-
epithelial fibrosis and airway hyper reactivity (Zhu et al, 
1999). By targeting a key transcription factor (STAT6), 
which is unique to this pathway, we are able to stem the 
ongoing inflammatory response initiated by epithelial cell 
exposure to IL-13.     
 
We have previously demonstrated the use of siRNA to 
ablate STAT6 messenger RNA and protein (Walker et al, 
2009), and demonstrated that this was an effective 
approach to rapidly achieve attenuation of ongoing IL-13 402 
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mediated events in lung epithelial cells (Walker et al, 
2009). 
 
Here, we expand this work and demonstrate the screening 
of the entire STAT6 gene to identify suitable siRNA 
available for potential therapeutic development. We then 
show that chemical modification, to prevent degradation in 
vivo, can be achieved without detectable loss of efficacy 
and identify lead candidates for future pre-clinical 
development. 
 
MATERIALS AND METHODS 
 
Cell cultures  
The human A549 lung epithelial cell line was obtained 
from European Collection of Cell Cultures (ECACC, 
Salisbury, UK) and routinely cultured in Dulbecco’s 
modified Eagle’s minimal essential medium (DMEM) 
containing 10% (v/v) heat inactivated fetal bovine serum 
(HIFBS) (Invitrogen, UK) and 1% (w/v) penicillin/ 
streptomycin solution (Sigma-Aldrich, UK). Subconfluent 
cultures were split using trypsin/ethylene-
diaminetetraacetic acid (EDTA) (Invitrogen, UK). 
 
Transfection 
For transfection with siRNAs, 4x10
4 cells were seeded 
into each well of a 12-well tissue culture tray  (Greiner 
Bio-One, UK) in 1ml DMEM containing 10% (v/v) 
HIFBS without antibiotics (unless otherwise stated).  Cells 
were cultured at 37°C in a humidified 5% (v/v) CO2 
environment for 24hr prior to transfection. siRNAs were 
then diluted to the desired concentration in OptiMEM 
serum-free medium (Invitrogen, UK) and transfections 
were performed using the chemical transfection agent 
Interferin™ (Poly Plus-Transfection, Inc) in accordance 
with the manufacturer’s instructions. Following 
transfection, cells were incubated at 37°C in a humidified 
5% (v/v) CO2 environment for 72hr before sample 
collection. In certain experiments cells were cultured in 
the presence of recombinant human IL-13 (PeproTec EC, 
UK) at a final concentration of 50ng/ml for the last 24hr of 
the culture, or Poly (I:C) (Sigma-Aldrich, UK) at the final 
concentrations indicated. For experiments to test for 
interferon responses, cells were only cultured for 24hr 
following transfection before sample collection. 
 
siRNAs 
Unmodified siRNAs were purchased from Ambion Inc 
(Austin, TX), whilst modified siRNA were synthesised as 
single strands by Integrated DNA Technologies Inc, 
(Belgium). Annealing of the siRNA single strands was 
performed by mixing equal molar concentrations of each 
strand, heating to 90°C and then allowing cooling to room 
temperature. Confirmation of successful annealing was 
achieved on 15% (w/v) TBE-Urea polyacrylamide gels 
followed by visualisation with ethidium bromide (Sigma-
Aldrich, UK) under UV light using a gel doc machine 
(Bio-Rad, UK).  Scrambled control siRNA was Silencer® 
Negative Control #1 (Ambion, UK). 
 
siRNA modification 
In order to improve the in vivo stability, chemical 
modification of the siRNA was performed. The following 
chemical modifications were included in the siRNA 
design: 
 
• Deoxyribonucleotide Adenosine, Uracil, Guanine and 
Cytosine (A, U, G, C) 
• 2’ O-Methyl modified Adenosine or Guanine (
mA, 
mG) 
• Internal 2’ Fluoro modified Cytosine and Uracil (
i2FC, 
i2FU) 
• Phosphorothioate linkages (*) 
 
Gene expression analysis  
Total RNA was isolated from Tri-Reagent® (Sigma-
Aldrich, UK) and first strand cDNA synthesis carried out 
from 1µg RNA using the High Capacity cDNA synthesis 
kit (Applied Biosystems, UK). Quantitative and semi-
quantitative real-time PCR was performed in a duplex 
reaction. This used TaqMan gene expression assays with a 
FAM probe (Applied Biosystems, UK) to the target gene 
and the TaqMan control assay (Applied Biosystems, UK) 
to the house keeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) with a VIC-TAMRA probe.   
PCR master mix used was the TaqMan universal PCR 
master mix, no Amperase UNG (Applied Biosystems, UK) 
and reaction ratios were as per the manufacturer’s 
instructions.   
 
Standard PCR conditions were 95°C for 10min, followed 
by 40 cycles of 95°C for 15sec and 60°C for 60sec with 
fluorescence quantification after each anneal/extension 
step. The expression of each gene was normalised against 
the expression of the house keeping gene GAPDH. For 
STAT6 analysis, quantification was performed using a 
standard curve of recombinant human STAT6 and results 
expressed as a percentage of total STAT6 remaining 
compared to a transfection reagent only (negative) control. 
For other genes, gene expression was compared to relative 
expression in the presence of transfection reagent only 
using the method described by Pfaffl (2001). 
 
Measurement of protein expression by western blotting 
and enzyme-linked immunosorbent assay (ELISA) 
Western blotting for STAT6 and GAPDH was performed, 
as previously described (Walker et al, 2009). Protein 
densitometry analysis was carried out using the Bio-Rad 
Quantity One
TM software. ELISA for human CCL26 
(Eotaxin 3) was performed as previously described 
(Walker et al, 2009).   
 
THP-1 interferon assay 
The human THP-1 monocyte cell line was obtained from 
European Collection of Cell Cultures (ECACC, Salisbury, 
UK) and routinely cultured in Roswell Park Memorial 
Institute (RPMI)-1640 medium containing 10% (v/v) heat 
inactivated fetal bovine serum (HIFBS) (Invitrogen, UK) 
and 1% (w/v) penicillin/streptomycin solution (Sigma-
Aldrich, UK) in a suspension culture. 
 
For transfection, cells were removed from culture, washed 
and seeded into 6-well tissue culture trays (Greiner Bio-
One, UK) in 2ml RPMI-1640 containing 10% (v/v) HIFBS 
without antibiotics. 12-O-tetradecanoylphorbol-13-acetate 
(TPA) was then added to each well of the trays at a final 
concentration of 200ng/ml and cells cultured at 37°C in a 403 
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humidified 5% (v/v) CO2 environment for 72hr to induce 
maturation to a macrophage phenotype, which causes them 
to stop dividing and adhere to the well plastic. After 72hr, 
the medium containing TPA was removed from the wells 
and 2ml fresh RPMI-1640 plus 10% (v/v) HIFBS added.  
Transfection was then carried out as described above in 
‘Transfection’.  
 
Statistical and Data analysis 
Data from multiple experiments are expressed as mean ± 
standard deviation. For mRNA fold-change data, 
differences between groups were examined for statistical 
significance using the Mann–Whitney U-test. Quantitative 
measurements were compared using Student’s t-test. In all 
cases, p values <0.05 were considered significant. 
 
IC50 values were determined using the IDBS™ XLfit 
Excel add-in analysis package. 
 
RESULTS 
 
Design of siRNAs for the STAT6 gene 
Initial bioinformatic screening of the STAT6 gene using 
NCBI BLAST® was carried out to select possible 
candidates for in vitro screening. This process involved 
breaking down the human STAT6 nucleotide sequence 
(GeneBank Seq ID: NM_003153) into all possible 19-
mers, which were then aligned against the target 
sequences for mouse, rat and non-human primate 
(Rhesus) STAT6 (GeneBank Seq ID’s: NM_009284.2, 
NM_001044250 and XM_001115590.1, respectively). 
Only those sequences, which aligned with all four 
species, were carried forward.    
 
A hierarchy of the 19-mers was then constructed. 19-mers 
with perfect sequence identity across all four of the target 
species were placed at the top followed by 19-mers with 
increasing degeneracy. Degeneracy was defined as 
follows: Wobble pairs were considered less of a problem 
then mis-pairs and gaps were considered the most 
degenerate. Any 19-mers with a run of four or more 
guanine bases was pushed down the list due to the 
manufacturing challenges inherent to such sequences, 
which are known to form polymorphic structures (Dai et 
al, 2007; Zhang et al, 2010).   
 
Sequences were then blasted against the whole GenBank 
database using NCBI BLAST® to identify potential off- 
target silencing.  Identities of 16 or more bases were noted 
and if the gene affected was of concern, the 19-mer was 
moved down the list.  Finally, a visual inspection of the 
sequences was carried out to finalise the hierarchy.   
Tighter base pairing at the 3’-end of the antisense relative 
to the 5’-end can be a benefit (Ui-Tei et al, 2004; Rana, 
2007) and therefore was used as a criterion to move a 19-
mer up the hierarchy. Purines and most favourably 
adenosines at the 5’-end of the anti-sense strand were also 
preferentially selected for to favour stabilisation chemistry 
if required (Ui-Tei et al, 2004; Rana, 2007).  
 
This selection process left forty siRNA candidates to be 
taken forward for in vitro screening, which were 
designated the numbers 1 to 40. 
Characterisation of STAT6 siRNA activity 
Forty siRNAs were screened for inhibitory activity.   
Their ability to inhibit STAT6 expression at the mRNA 
and protein level was assessed using a quantitative (q) 
polymerase chain reaction (PCR) and western blotting, 
respectively. STAT6 mRNA in A549 cells was analysed 
after transfection with each of the siRNA at a final 
concentration of 1nM.  Figure 1 shows STAT6 mRNA 
remaining (relative to the transfection control) for those 
siRNA, which produced significant (p<0.05) 
knockdown compared to the scrambled and untreated 
controls (21 out of the 40). The relative binding 
positions of each of these siRNAs within the STAT6 
gene are illustrated in the schematic in Figure 1, 
demonstrating localisation to exons 6, 9, 13, 15, 16 and 
17. siRNAs that did not produce significant STAT6 
knockdown (not shown) were also found to localise to 
exons 6, 9, 13, 15 and 16. Western blotting was then 
performed to determine the degree of STAT6 protein 
knockdown following siRNA treatment at 1nM. Figure 
2 shows a representative blot demonstrating the 
presence or absence of STAT6 protein for siRNAs 1-8.  
The relative STAT6 band densities for those siRNAs, 
which produced significant (p<0.05) knockdown 
compared to the scrambled and untreated controls (20 
out of 40), is also shown (Figure 2). 
 
Candidates for the next phase of testing were selected on 
the basis of significant STAT6 mRNA and protein 
knockdown, which left fourteen siRNA that were 
subjected to a second NCBI BLAST® analysis. This 
identified theoretical mis-match events and/or potential 
off-target effects in at least one of the four target 
species, in seven of the siRNAs. As a result these seven 
siRNAs were designated as backup development 
candidates, leaving siRNAs 2, 5, 7, 17, 20, 29 and 34 for 
further development (siRNA sequence information is 
shown in Table 1). 
 
Determination of the 50% inhibitory concentration 
(IC50) for unmodified siRNA 
IC50 values for each of the seven lead siRNA (Figure 3 and 
Table 1) were next determined by repeating the transfection 
experiments with a range of siRNA concentrations from 
0.1nM to 100nM. Results demonstrated that all seven of 
the siRNAs were highly efficacious with IC50 values in 
A549 cells of less than 2nM in all cases and less than 1nM 
for siRNAs 2, 5, 7, 17 and 20. 
 
Determination of the 50% inhibitory concentration 
(IC50) for chemically modified siRNA 
IC50 experiments were then repeated for modified 
versions of each of the siRNA (Figure 3 and Table 1).  
Modification of siRNAs 7, 17, 20 and 34 led to a 10-15 
fold increase in IC50 value in A549 cells, whilst the 
reduction in efficacy for siRNA 29 following 
modification was so pronounced (> 100-fold) that it was 
not possible to determine an IC50 within the 
concentration range of the experiment (0.1 to 100nM). 
No significant reduction in efficacy was noted for 
siRNAs 2 and 5 following modification; therefore, 
siRNAs 2 and 5, with and without modification were 
taken forward for further development. 404 
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Figure 1. A. Treatment of A549 cells with STAT6 siRNA ablates STAT6 mRNA expression. Percentage of STAT6 mRNA 
remaining relative to the transfection control in A549 cells transfected with siRNA to STAT6 at a final concentration of 1nM. Only 
siRNA which produced significant (p<0.05) STAT6 knockdown compared to the scrambled (SC) and untreated (UNT) controls are 
shown. Values shown are mean (n=3), + standard deviation. B. Schematic shows exons six to seventeen of the STAT6 gene together 
with the relative positions of siRNA that produced significant knockdown of STAT6 mRNA. 
 
 
 
A: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
Figure 2. Treatment of A549 
cells with STAT6 siRNA ablates 
STAT6 protein expression. A. 
Percentage of STAT6 protein 
remaining relative to the 
transfection control in A549 cells 
transfected with siRNA to 
STAT6 at a final concentration 
of 1nM.  Only siRNA which 
produced significant (p<0.05) 
STAT6 knockdown compared to 
the scrambled (SC) and untreated 
(UNT) controls are shown.  
Values shown are mean (n=3), + 
standard deviation. B. Western 
blot of siRNA 1 to 8, showing 
the absence of STAT6 protein in 
A549 cells treated with siRNA 1 
to 7 at a final concentration of 
1nM.  Complete protein 
knockdown was not observed for 
siRNA 8. S = scrambled control; 
+ = positive control (st6-1)
18; T = 
Transfection reagent control; U = 
untreated control; J = Jurkat cell 
lysate. 405 
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Table 1. Sequence information and IC50 values (nM) for each of the lead seven (unmodified and modified) siRNA.  For unmodified 
siRNA all bases are RNA except for ‘tt’ overhangs, which are DNA thymidine bases.  For modified siRNA the following 
nomenclature is used: r = RNA base, m = 2’ O-Methyl modification, i2F = internal 2’ fluoro modification, * = phosphorothioate 
linkage and bases with no prefix are DNA. Sequences shown are protected under UK law by patent application number 1007221.3 
(Allerna Therapeutics Ltd). ND = Not determined. 
 
siRNA Strand  Sequence (5’ → 3’)  IC50 (nM) 
2 
Sense  GCA  GGA  AGA  ACU  CAA  GUU  Utt 
0.31 
Antisense  AAA  CUU  GAG  UUC  UUC  CUG  Ctt 
Mod 2 
Sense 
rG
i2FC
rA  
rG
rG
rA  
rA
rG
rA  
rA
i2FC
i2FU  
i2FC
rA
rA  
rG
i2FU
i2FU  
i2FU*t*t 
0.4 
Antisense 
rA
rA
rA  
i2FC
i2FU
i2FU  
mG
mA
mG  
i2FU
i2FU
i2FC  
i2FU
i2FU
i2FC  
i2FC
i2FU
mG  
i2FC*t*t 
5 
Sense  GAA  GCA  GGA  AGA  ACU  CAA  Gtt 
0.87 
Antisense   CUU  GAG  UUC  UUC  CUG  CUU  Ctt 
Mod 5 
Sense 
rG
rA
rA  
rG
i2FC
rA  
rG
rG
rA  
rA
rG
rA  
rA
i2FC
i2FU  
i2FC
rA
rA  
rG*t*t  
0.79 
Antisense    
i2FC
i2FU
i2FU  
mG
mA
mG  
i2FU
i2FU
i2FC  
i2FU
i2FU
i2FC  
i2FC
i2FU
mG  
i2FC
i2FU
i2FU  
i2FC*t*t  
7 
Sense  CAU  UCU  CUG  CCA  AAG  ACC  Utt 
0.8 
Antisense  AGG UCU UUG GCA GAG AAU Gtt  
Mod 7 
Sense 
i2FC
rA
i2FU  
i2FU
i2FC
i2FU  
i2FC
i2FU
rG  
i2FC
i2FC
rA  
rA
rA
rG  
rA
i2FC
i2FC  
i2FU*t*t  
9.83 
Antisense 
rA
rG
rG  
i2FU
i2FC
i2FU  
i2FU
i2FU
mG  
mG
i2FC
mA  
mG
mA
mG  
mA
mA
i2FU  
mG*t*t 
17 
Sense  CCA  AGA  CCC  GGG  CAU  CGC  Utt  
0.17 
Antisense  AGC  GAU  GCC  CGG  GUC  UUG  Gtt  
Mod 17 
Sense 
i2FC
i2FC
rA  
rA
rG
rA  
i2FC
i2FC
i2FC  
rG
rG
rG  
i2FC
rA
i2FU  
i2FC
rG
i2FCC  
i2FU*t*t  
8.57 
Antisense 
rA
rG
rC  
mG
mA
i2FU  
mG
i2FC
i2FC  
i2FC
mG
mG  
mG
i2FU
i2FC  
i2FU
i2FU
mG  
mG*t*t  
20 
Sense  AUG  CCU  UCU  CUG  AGA  UGG  Att  
0.66 
Antisense  UCC  AUC  UCA  GAG  AAG  GCA  Utt  
Mod 20 
Sense    
rA
i2FU
rG  
i2FC
i2FC
i2FU  
i2FU
i2FC
i2FU  
i2FC
i2FU
rG  
rA
rG
rA  
i2FU
rG
rG  
rA*t*t  
12.91 
Antisense    UCC  A
i2FU
i2FC  
i2FU
i2FC  AGA  GAA  GG
i2FC  A
i2FU*t*t 
29 
Sense  GCA  GUG  GUU  UGA  UGG  UGU  Ctt  
1.16 
Antisense  GAC  ACC  AUC  AAA  CCA  CUG  Ctt  
Mod 29 
Sense 
rG
i2FC
rA  
rG
i2FU
rG  
rG
i2FU
i2FU  
i2FU
rG
rA  
i2FU
rG
rG  
i2FU
rG
i2FU  
i2FC*t*t  
ND 
Antisense 
rG
rA
rC  
mA
i2FC
i2FC  
mA
i2FU
i2FC  
mA
mA
mA  
i2FC
i2FC
mA  
i2FC
i2FU
mG  
i2FC*t*t  
34 
Sense  GGU  UUG  AUG  GUG  UCC  UGG  Att  
1.71 
Antisense  UCC  AGG  ACA  CCA  UCA  AAC  Ctt  
Mod 34 
Sense 
rG
rG
i2FU  
i2FU
i2FU
rG  
rA
i2FU
rG  
rG
i2FU
rG  
i2FU
i2FC
i2FC  
i2FU
rG
rG  
rA*t*t  
16.04 
Antisense 
rU
rC
rC  
mA
mG
mG  
mA
i2FC
mA  
i2FC
i2FC
mA  
i2FU
i2FC
mA  
mA
mA
i2FC  
i2FC*t*t  
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60 Figure 3. A. Example IC50 curve plot 
from IDBS™ XLfit analysis package 
demonstrating the plotted IC50 line (dash) 
for siRNA 2. Values shown are mean 
(n=3) ± standard deviation. B. IC50 values 
for the lead seven siRNA before and after 
chemical modification.  No STAT6 
mRNA knockdown was observed for 
siRNA Mod 29 within the concentration 
range tested, therefore an IC50 value could 
not be determined. Modification of 
siRNAs 7, 17, 20 and 34 lead to a 10-15 
fold reduction in efficacy compared to the 
unmodified siRNA.  No significant 
efficacy reduction was noted for siRNA 2 
and 5 following modification.  Values 
shown are mean (n=3) + standard 
deviation. Note log scale.  406 
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Attenuation of Eotaxin 3 (CCL26) responses 
We previously demonstrated that STAT6 siRNA potently 
suppress ongoing inflammatory events in the presence of 
inflammatory cytokines (Walker et al, 2009). We also 
demonstrated that CCL26 (eotaxin 3) is the predominant 
eotaxin chemokine up-regulated in A549 cells in response 
to the inflammatory cytokine IL-13 and that there is no 
significant difference between IL-13 and IL-4 in terms of 
ability to up-regulate eotaxin mRNA expression (Walker et 
al, 2009). We therefore utilised the up-regulation of CCL26 
mRNA and protein as a functional downstream test of the 
robustness of STAT6 ablation in our model system. A549 
cells treated with IL-13 (50ng/ml) for 24hr show a 
significant up-regulation in CCL26 gene and protein 
expression (Figure 4). Treatment with unmodified siRNA 2 
or 5 significantly (p<0.05) reduced CCL26 gene expression 
and completely ablated protein expression at all 
concentrations tested. Modification of siRNAs 2 and 5 
demonstrated approximately a 10-fold reduction in efficacy, 
with the higher concentrations tested still showing 
attenuation of CCL26 gene expression and complete loss of 
protein expression. No reduction in gene expression was 
noted following treatment with modified siRNA at 0.1nM 
although a significant reduction in protein expression 
compared to the untreated control was still observed. 
 
Interferon responses 
The presence of interferon responses associated with long 
double stranded RNA has been reported in previous siRNA 
studies (Bridge et al, 2003; Sledz et al, 2003). We therefore, 
carried out screening by RT-PCR for interferon (IFN)-α, 
IFN-β and the interferon induced gene 2’5’-oligoadenylate 
synthase (OAS)-1. No significant up-regulation of either 
IFN-β or OAS-1 was noted following the transfection of 
A549 cells with either modified or unmodified siRNA 
(50nM) compared to untreated control cells. Treatment with 
Poly I:C (1µg/ml) however did produce a significant 
(p<0.05) up-regulation of both genes (Figure 5).  
 
We then further tested one of our siRNA sequences in a 
THP-1 cell based interferon assay, which we had found to 
be more sensitive to stimulation with double stranded RNA, 
requiring only 0.01µg/ml of Poly I:C to generate significant 
up-regulation of the IFN–α and IFN-β genes.  Stimulation of 
THP-1 cells with either the modified or unmodified siRNA 
2 molecule (at 50 or 100nM) produced no significant 
(p>0.05) up-regulation of the IFN-α and IFN-β genes 
compared to untreated control cells (Figure 5). Treatment 
with Poly I:C (0.01µg/ml) however did produce a 
significant (p<0.05) up-regulation of both genes (Figure 5). 
 
Despite previous studies suggesting the presence of 
interferon responses to siRNA, these data corroborate our 
previous work (Walker et al, 2009), which demonstrated 
that our STAT6 siRNA do not induce an interferon 
response. 
 
DISCUSSION 
 
The complexity of the asthma phenotype and complications 
associated with current treatment regimens point to the 
need for an effective, side-effect-free approach to the 
treatment of asthma. Several groups have demonstrated that 
the IL-13 pathway is a key mediator of airway hyper-
reactivity, mucus production and eosinophilia within the 
asthmatic lung (Wills-Karp et al, 1998; Wills-Karp, 2001; 
Yang et al, 2001; Kuperman et al, 2002; Izuhara et al, 
2006; Bree et al, 2007). Central to this signalling pathway 
is STAT6, the importance of which has been demonstrated 
with gene-knockout mice (Akimoto et al, 1998; Kuperman 
et al, 2002) and in studies of human disease 
(Christodoulopoulos et al, 2001; Mullings et al, 2001). We 
previously showed that an RNAi-based strategy offers 
superior targeting of STAT6 gene expression within the 
A549 lung epithelial cell-line (Walker et al, 2009). We also 
demonstrated the suitability of this model through 
similarity of IL-13 responsiveness and STAT6 knockdown 
by RNAi with cultured primary small airway epithelial 
cells and bronchial smooth muscle cells (Walker et al, 
2009). Thus having previously designed efficacious 
STAT6 siRNA, we sought to derive all STAT6 siRNA 
suitable for pre-clinical in vivo testing and explore 
chemical modification with a view to facilitate in vivo 
studies. 
 
We therefore developed a rapid screening capability 
through a combination of in silico and in vitro approaches, 
which enabled us to determine those siRNA suitable for 
further  in vivo characterisation. Pre-clinical character-
isation of siRNA requires the use of animal models for 
efficacy and toxicity studies. Thus, in addition to the 
human STAT6 sequence we utilised GeneBank STAT6 
sequences for three species likely to be used as part of a 
pre-clinical development programme, mouse, rat and non-
human primate. By aligning potential siRNA sequences 
against STAT6 sequences from all four species and then 
ranking them within a hierarchy based on sequence and 
manufacturing suitability, we were able to significantly 
reduce the size of our siRNA pool. This served to facilitate 
a more rapid in vitro screening process and also ensured 
we avoided siRNA that may require complicated and 
expensive manufacturing processes. The suitability of this 
approach is exemplified by the fact that our in silico 
process delivered fourteen highly efficacious siRNA, 
which when transfected into A549 cells at 1nM, produced 
significant (p<0.05) STAT6 mRNA and protein 
knockdown compared to scrambled and untreated controls.   
Further characterisation of our lead candidates 
demonstrated that all exhibited highly efficacious IC50 
values between 0.1 and 2nM suggesting all would be 
suitable for in vivo characterisation. However, despite 
studies demonstrating successful RNAi-mediated gene 
targeting within mouse lung tissues (Massaro et al, 2004; 
Bitko et al, 2005; Thomas et al, 2007; Darcan-Nicolaisen 
et al, 2009), we considered chemical modification of our 
siRNA as a means to improve in vivo stability and 
therefore increase the likely efficacy of candidates taken 
forward for in vivo development. The rationale for 
modification was predicated on the assumption of benefit 
if both strands possess increased resistance to degradation. 
While this concept has not yet been tested, we assumed the 
more critical anti-sense strand should contain the greatest 
stabilisation and therefore allowed an imbalance favouring 
degradation of the sense strand after RISC loaded onto the 
target site.   Thus, all sense strands were modified with 2’-
fluoropyrimidines whilst the A and G purines remained407 
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Figure 4. Treatment of A549 cells with siRNA attenuates CCL26 responses in the presence of the inflammatory cytokine IL-13.  A. 
Fold change in expression of the CCL26 gene following treatment of A549 cells with IL-13 for 24hr.  Significant (p<0.05) reduction 
in CCL26 expression was noted at all concentrations for unmodified siRNA 2 and 5 compared to the untreated control.  Modification 
led to a slight reduction in efficacy meaning that a significant reduction in expression was only noted for the two higher 
concentrations of siRNA.  B. CCL26 protein expression was completely ablated by both unmodified siRNA.  Modified siRNA 
completely ablated protein expression at 10 and 1nM, whilst at 0.1nM protein expression was significantly (p<0.05) reduced 
compared to the untreated control.  No protein was detected in samples without bars.  SC = Scrambled control, TF = transfection 
reagent only control, UNT = untreated control.  Values shown are mean (n=3) + standard deviation. 408 
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Figure 5. A. Interferon responses following the treatment of A549 cells with modified and unmodified STAT6 siRNA at 50nM.  
Treatment with Poly I:C (1µg/ml) produced a significant (p<0.05) up-regulation in the expression of IFN-β and OAS-1. Treatment with 
either modified or unmodified siRNA 2 or 5 did not produce any significant up-regulation of IFN-β or OAS-1 compared to untreated 
control cells (p>0.05).  TF = transfection reagent only control, UNT = untreated control.  Values are mean (n=3) ± standard deviation. B. 
Interferon responses following the treatment of THP-1 cells with modified and unmodified STAT6 siRNA at 50 or 100nM.  Treatment 
with Poly I:C (0.01µg/ml) produced a significant (p<0.05) up-regulation in the expression of IFN-α and IFN-β.  Treatment with either 
modified or unmodified siRNA 2 did not produce any significant up-regulation of IFN-α or IFN-β compared to untreated control cells 
(p>0.05).  TF = transfection reagent only control, UNT = untreated control. Values are mean (n=3) ± standard deviation.   
 
 
natural ribose; the antisense strands were reinforced with 
additional 2’-Ome modification of their purines.   
Furthermore, we strove to maintain the critical 5’-terminus 
of the antisense strand in the least modified form possible.  
When the antisense strand contained purines at the three 5’ 
positions they remained as ribose. If any of the three 5’ 
positions included a pyrimidine it was modified due to its 
more nuclease sensitive nature. Typically, chemical 
modification of siRNA is associated with a loss in efficacy 
together with improved pharmacokinetics and reduced 
immune stimulation (Morrissey et al, 2005; Rana, 2007).  
We therefore subjected chemically modified forms of our 
siRNA to further IC50 analysis to determine any efficacy 
loss associated with modification. Whilst five of our seven 
leads demonstrated losses in efficacy consistent with the 
literature (Morrissey et al, 2005; Rana, 2007), we also 
noted two candidates that showed no significant (p>0.05) 
reduction in IC50 value (in terms of STAT6 mRNA 
knockdown) compared to their unmodified forms within 
our A549 model. It is also acknowledged that an 
exhaustive analysis of chemically modified sequences is 
not possible. Therefore, we cannot exclude the possibility 
of siRNAs with both increased activity and stability. In 
particular, it is noted that the use of 3’dTdT overhangs has 
been shown to reduce the duration of action of siRNA both 
in vitro and in vivo (Hohjoh, 2002; Strapps et al, 2010).  
We will therefore look to testing alternative 3’-overhang 
chemistry in the future studies. 
 
The allergic asthmatic lung is characterised by the 
infiltration of eosinophils into peribronchial sites, which 
occurs under the control of IL-13. Secretion of IL-13 by 
lymphocytes within the lung leads to local production of 
eotaxin chemokines, which act as chemo-attractants 
recruiting eosinophils to the airways where subsequent 
degranulation leads to airway damage and remodelling 
(Davies et al, 2003). The importance of the eotaxin family 
of chemokines to the asthma phenotype and their 
association with airway remodelling and fibrosis (Joubert 
et al, 2005; Beck et al, 2006), led us to suggest that 
blockade of the eotaxin pathways will likely be an 
essential component of future asthma therapeutics. We 
subsequently demonstrated that RNAi of STAT6 
prevented IL-13-mediated eotaxin family mRNA 
induction and ablated functional CCL26 protein 
expression (Walker et al, 2009). Within the current study 
we have again demonstrated that our lead siRNA 
candidates, both modified and unmodified, potently ablate 409 
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both CCL26 mRNA and protein expression in the presence 
of IL-13. CCL26 analysis however, did provide a 
differentiator between modified and unmodified siRNA. 
Whilst at the STAT6 mRNA level no significant 
difference was noted between the modified and 
unmodified versions of our lead siRNA, CCL26 ablation 
did show a difference. At the lowest concentration tested 
(0.1nM), neither modified siRNA 2 or 5 produced 
significant knockdown of CCL26 mRNA or protein, whilst 
the unmodified forms did. Whilst this finding suggests 
reduced efficacy following modification corroborating 
findings within the literature, we have still shown that 
chemical modification of siRNAs to achieve in vivo 
stability is possible with only minimal loss of efficacy.   
Furthermore, work to characterise these siRNAs in vivo is 
required to demonstrate the balance of improved longevity 
in vivo against target knockdown efficacy. 
 
In addition to improved in vivo longevity, another 
important facet of the chemical modification of siRNAs is 
to prevent the induction of interferon responses, which 
have been reported in the literature (Bridge et al, 2003; 
Sledz et al, 2003). Within the current study we have 
demonstrated an absence of interferon activation in two 
human cell culture systems suggesting that our siRNA 
molecules do not induce such a response. In addition to 
toll-like receptor (TLR) 3 mediated immune stimulation 
(already investigated herein), several groups also report 
the immunostimulatory effects of siRNA via TLR 7 and 8 
(Hornung et al, 2005; Judge et al, 2005). Whilst it will 
clearly be important to test for such an effect in future in 
vivo work, within the current study such investigation is 
not appropriate for a number of reasons. As a potential 
asthma therapeutic, the predominant cell type targeted by 
our siRNA will be airway epithelial cells, which express 
TLR 3 but not TLR 7 or 8. Whilst dendritic cells will 
undoubtedly be encountered within the lung, the 
appropriateness of a peripheral blood mononuclear cell 
(PBMC) model is diminished since we are not considering 
intravenous (iv) as a potential route of administration, 
rather inhalation. It has been demonstrated that the 
administration of naked siRNAs (without any delivery or 
transfection agent) fails to generate any interferon 
responses (Hornung et al, 2005; Judge et al, 2005). Our 
own work also corroborates this finding, whereby the 
administration of Poly IC to our cell models without a 
transfection reagent failed to stimulate the up-regulation of 
interferon α/β mRNA (data not shown). As a result, work 
demonstrating TLR 7/8 mediated responses incorporated 
the use of microencapsulation to facilitate siRNA uptake. 
This coupled with the iv administration route chosen, 
would have specifically targeted the TLR 7/8 rich 
endosomal compartment of dendritic cells, providing an 
opportunity for TLR 7/8 stimulation. Although, our use of 
the PEI based transfection reagent Interferin™ would also 
target this compartment, such reagents have been shown to 
facilitate quick exit from the endosome by inducing rapid 
proton influx and endosomal swelling and rupture (Akinc et 
al, 2005). Such a mechanism would significantly reduce the 
time available for endosomal degradation and also likely 
negate the possibility of endosomally localised TLR 
stimulation.  As a consequence, we chose to only employ 
TLR 3 stimlation as a factor within our in vitro screening 
system. Further in vivo testing however, will enable us to 
determine whether the non-stimulatory nature of our siRNA 
is only true within an in vitro culture system and our 
modifications may then accrue further benefit once in vivo. 
 
Several studies have now been published demonstrating 
the use of RNAi to target epithelial cell STAT6 both in 
vitro and in vivo (Rippman et al, 2005; Darcan-Nicolaisen 
et al, 2009; Walker et al, 2009). Other studies however, 
have used high concentrations of siRNA and failed to 
show complete inhibition of expression of STAT6 and/or 
downstream signalling events. As previously, our 
extensive dose response analyses have demonstrated that 
effective inhibition of expression of STAT6 and 
downstream signalling events can be achieved with low 
concentrations of non-interferon-inducing STAT6 
targeting siRNA. Furthermore, we have shown that it is 
possible to achieve knockdown at these concentrations 
with siRNA chemically modified to improve in vivo 
stability and therefore increase the likely in vivo efficacy.  
These data support the suitability of STAT6 as an 
important and viable target for the therapy of asthma and 
further work within our lab will test the therapeutic 
potential of STAT6 siRNA within the asthmatic model. 
 
CONCLUSIONS 
 
 The IL-13 pathway and its associated transcription 
factor, STAT6, have been clearly implicated in the 
pathogenesis of bronchial asthma. 
 
 Identification of efficacious siRNA to STAT6 was 
achieved through the use of a combined in silico and in 
vitro screening approach. 
 
 Chemical modification strategy achieved without 
significant loss of in vitro efficacy. 
 
 Several STAT6-targetting siRNA suitable for pre-
clinical development were identified. Further work will 
investigate in vivo efficacy. 
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